Jenny suggests a larger phase 3 trial will be necessary. Jenny...

Jenny suggests a larger phase 3 trial will be necessary.

Jenny isn't the only one who has been suggesting that - just sayin' The new CEO hinted at that as well in her ASX Business Update dated 22 May 2024 on page 3 and some of us on here predicted that after reviewing the phase 2 results last year.







I would be disappointed if Starpharma/partner/licensee do not try for a 505(b)(2) pathway with their existing data


IMO I would prepare to be disappointed then because if the DEP phase 2 results were even half as good as many of you have claimed on here ad nauseum:

1. we would have seen big pharma clambering over each other to sign a DEP license deal and subsequently make a 505(b)(2) application; or


2. we would have seen Starpharma make their own 505(b)(2) application to the FDA.


Bottom line - we haven't seen either so ask yourself why is that if the DEP data / science is so good ?


..... and don't even get me started on why no one even wants to take over the company while the market cap is this low